Hard to say whether this will have a material change to revenues. Per the 2022 annual report, Hizentra sales were up 20% during 2022 and is the market leading product for subcutaneous immunoglobulin products.
Page 15 of the annual report shows that patients have a preference for Hizentra for at home dosing, so the pre-filled syringe is an obvious move to make.
Appears to not be all upside as this has lead to a decline in Privigen sales.
DYOR, IMO, blah blah
News: CSL Csl Behring Receives FDA Approval For Hizentra® (Immune Globulin Subcutaneous <Origin..., page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$262.78 |
Change
7.470(2.93%) |
Mkt cap ! $127.0B | |||
| Open | High | Low | Value | Volume |
| $258.12 | $263.22 | $257.91 | $71.96M | 275.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 19 | $262.76 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $262.83 | 44 | 4 |
View Market Depth
| Last trade - 10.58am 22/07/2025 (20 minute delay) ? |
| CSL (ASX) Chart |